. Author manuscript; available in PMC: 2019 Apr 15.

Published in final edited form as: Cancer. 2018 Jan 25;124(8):1760–1769. doi: 10.1002/cncr.31241

Table-3.

Patient characteristics and disease-site specific prognostic factors according to Hispanic ethnicity and clinical trial subgroup analysis (patients with complete data).

Type of cancer	Percent of patients in high risk categories (% of all Hispanics vs. % of all non-Hispanics)
Type of cancer	≥65yo	Female¹	African American	Education≤ U.S. median	Income≤ U.S. median	Disease-site specific prognostic factors
Adjuvant breast ER− and PR−	6 vs. 8		3 vs. 13^*	68 vs. 32^*	68 vs. 49^*	Tumor>5 cm: 20 vs. 8^*	Post-menopausal: 40 vs. 48^*	≥ 4 nodes: 9 vs. 13
Adjuvant breast ER+ and/or PR+	5 vs. 14^*		2 vs. 7^*	70 vs. 29^*	66 vs. 45^*	Tumor>5 cm: 13 vs. 8^*	Post-menopausal: 51 vs. 56^*	≥ 4 nodes: 29 vs. 22^*
Advanced breast ER+ and/or PR+	30 vs. 42		5 vs. 10	53 vs. 31^*	70 vs. 53^*	Post-menopausal: 95 vs. 93	Her2negative: 92 vs. 88
Advanced colorectal	19 vs. 41^*	41 vs. 41	2 vs. 14^*	83 vs. 41^*	78 vs. 59^*	Performance status 2: 11 vs. 10
Adjuvant gastric	20 vs. 35^*	42 vs. 26^*	2 vs. 20^*	72 vs. 47^*	72 vs. 62	≥4 nodes: 32 vs. 43	Stage T3-T4: 66 vs. 68
Adjuvant colorectal	28 vs. 38	43 vs. 41	0 vs. 7^*	74 vs. 34^*	76 vs. 56^*	N2–3 nodes: 26 vs. 31	Stage T3-T4: 89 vs. 85	Performance status 2: 8 vs. 3^*
Advanced prostate	52 vs. 67^*		2 vs. 21^*	77 vs. 38^*	67 vs. 56^*	Performance status ≥2: 13 vs. 11	Severity = Extensive: 79 vs. 74
Advanced prostate, hormone refractory	54 vs. 72^*		0 vs. 14^*	63 vs. 35^*	58 vs. 51	Extraskeletal metastasis: 58 vs. 53	Progression other than PSA: 89 vs. 81	Performance status ≥2: 12 vs. 9
AML	16 vs. 35^*	47 vs. 45	0 vs. 9^*	71 vs. 38^*	76 vs. 56^*	Performance status ≥2: 11 vs. 22
Advanced NSCLC	39 vs. 42	39 vs. 33	0 vs. 13^*	77 vs. 45^*	77 vs. 62	≥5% weight loss: 48 vs. 39	Abnormal LDH: 35 vs. 38	Stage IV: 81 vs. 89
Advanced aggressive NHL	8 vs. 16	32 vs. 40	0 vs. 10^*	62 vs. 35^*	73 vs. 53^*	IPI risk=High/High-Int.: 35 vs. 41
Advanced indolent NHL	20 vs. 12	36 vs. 43	4 vs. 4	44 vs. 32	56 vs. 50	IPI risk=High/High-Int.: 20 vs. 13
Multiple Myeloma	9 vs. 18	37 vs. 41	5 vs. 18^*	67 vs. 36^*	70 vs. 55	Stage III: 65 vs. 59
Advanced GIST	21 vs. 47^*	46 vs. 45	0 vs. 12	71 vs. 37^*	64 vs. 48	Performance status 3: 4 vs. 3	Measurable disease: 96 vs. 94
Total¹	17 vs. 28^*	41 vs. 40	2 vs. 11^*	70 vs. 33^*	68 vs. 51^*

Percent provided for the non-sex specific cancers only

Indicates a significant difference between Hispanic and non-Hispanic groups (p<0.05)